Prevention of small airway obliteration in a swine heterotopic lung allograft model

Journal of Heart and Lung Transplantation

Volumn 19, Issue 2, 2000, Pages 193-206

  Salminen, Ulla Stina ^a   Maasilta, Paula K ^a   Taskinen, Eero I ^a   Alho, Hanni S ^a   Ikonen, Tuija S ^a   Harjula, Ari L J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; CYCLOSPORIN A; EVEROLIMUS; MACROLIDE; METHYLPREDNISOLONE;

AIRWAY OBSTRUCTION; ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHIOLITIS; CARTILAGE; CARTILAGE CELL; DRUG BLOOD LEVEL; GRAFT FAILURE; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG ALVEOLUS; LUNG TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; SWINE; XENOTRANSPLANTATION;

ANIMALS; AZATHIOPRINE; BRONCHI; BRONCHIOLITIS OBLITERANS; DISEASE MODELS, ANIMAL; EPITHELIUM; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; SWINE; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033981750     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(99)00118-7     Document Type: Article

References (35)

1. Hosenpud J.D., Bennett L.E., Keck B.M., Fiol B., Boucek M.M., Novick R.J. The registry of the International Society for Heart and Lung Transplantation fifteenth official report - 1998 . J Heart Lung Transplant. 17:1998;656-658.
2. Griffith B.P., Hardesty R.L., Armitage J.M., et al. A decade of lung transplantation. Ann Surg. 218:1993;310-320.
3. Reichenspurner H., Girgis R.E., Robbins R.C., et al. Oblitrative bronchiolitis after lung and heart-lung transplantation. Ann Thorac Surg. 60:1995;1845-1853.
4. Kramer M.R. Bronchiolitis obliterans following heart-lung and lung transplantation. Respir Med. 88:1994;9-15.
5. Morris R.E., Huang X., Gregory C.R., et al. Studies in experimental models of chronic rejection Use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis . Transplant Proc. 27:1995;2068-2069.
6. Yuh D.D., Gandy K.L., Morris R.E., et al. Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant. 14:1995;1136-1144.
7. Fahrni J.A., Berry G.J., Morris R.E., Rose G.D. Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation. 63:1997;533-537.
8. Hausen B., Morris R.E. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Clin Chest Med. 18:1997;353-366.
9. Keenan R.J., Konishi H., Kawai A., et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 60:1995;580-584.
10. Horning N.R., Lynch J.P., Sundaresan S.R., Patterson G.A., Trulock E.P. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant. 17:1998;761-767.
11. O'Hair D.P., Cantu E., McGregor C., et al. Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant. 17:1998;864-868.
12. Ross D.J., Waters P.F., Levine M., et al. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation Preliminary experience . J Heart Lung Transplant. 17:1998;768-774.
13. Kroshus T.J., Kshettry V.R., Savik K., John R., Bolman R.M. 3rd. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg. 114:1997;195-202.
14. Scott J.P., Higenbottam T., Sharples L., et al. Risk factors for obliterative bronchiolitis in heart-lung transplant series. Transplantation. 51:1991;813-817.
15. Yousem S.A., Dauber J.A., Keenan R., Paradis I.L., Zeevi A., Griffith B.P. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans? Transplantation. 52:1991;306-309.
16. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative. Pharmagological properties in vitro and in vivo. Transplantation. 64:1997;36-42.
17. Schuurman H.-J., Cottens S., Fuchs S., et al. SDZ RAD, a new rapamycin derivative. Synergism with cyclosporine. Transplantation. 64:1997;32-35.
18. Schuurman H.-J., Schuler W., Ringers J., Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc. 30:1998;2198-2199.
19. Cole O.J., Shehata M., Rigg K.M. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Tranplant Proc. 30:1998;2200-2203.
20. Ikonen T., Uusitalo M., Taskinen E., et al. Small airway obliteration in a new swine heteroropic lung and bronchial allograft model. J Heart Lung Transplant. 17:1998;945-953.
21. Burke CM, Theodore J, Dawkin KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984;86:824-820.
22. Salminen U.S., Ikonen T., Uusitalo M., et al. Obliterative lesions in small airways in an immunosuppressed porcine heterotopic bronchial allograft model. Tranplant Int. 11:1998;S515-S518.
23. Mauck K.A., Hosenpud J.D. The bronchial epithelium a potential allogeneic target for chronic rejection after lung transplantation . J Heart Lung Transplant. 15:1996;709-714.
24. Yousem S.A., Ray L., Paradis I.L., Dauber J.A., Griffith B.P. Potential role of dendritic cells in bronchiolitis obliterans in heart-lung transplantation. Ann Thorac Surg. 49:1990;424-428.
25. Bando K., Paradis I.L., Similo S., et al. Obliterative bronchiolitis after lung and heart-lung transplantation an analysis of risk factors and management . J Thorac Cardiovasc Surg. 110:1995;4-13.
26. Keenan R.J., Zeevi A. Immunologic consequences of transplantation. Chest Surg Clin N Am. 5:1995;107-120.
27. Reichenspurner H., Vipal S., Nitschke M., et al. Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus. J Heart Lung Transplant. 17:1998;439-451.
28. Bando K., Paradis I.L., Komatsu K., et al. Analysis of time-dependent risks for infection, rejection and deaths after pulmonary transplantation. J Thorac Cardiovasc Surg. 109:1995;49-59.
29. Schulman L.L., Ho E., Reed E., et al. Immunologic monitoring in lung allograft recipients. Transplantation. 61:1996;252-257.
30. Koskinen P.K., Kallio E.A., Krebs R., Lemström K.B. A dose-dependent inhibitory effect of cyclosporine A on obliterative bronchiolitis of rat tracheal allografts. Am J Respir Crit Care Med. 155:1997;303-312.
31. Reichenspurner H., Huang X., Soni V., Shorthouse R., Berry G.J., Morris R.E. Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation. Surg Forum. 46:1995;456-458.
32. Al-Dossari G.A., Jessurun J., Bolman R.M. 3rd, et al. Pathogenesis of obliterative bronchiolitis. Possible roles of platelet-derived growth factor and basic fibroblast growth factor. Transplantation. 59:1995;143-145.
33. Kanno S., Fukuda Y. Fibronectin and tenascin in rat tracheal wound healing and their relation to cell proliferation. Pathol Int. 44:1994;96-106.
34. Uhal B.D., Joshi I., True A.L., et al. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol. 296:1995;L819-L828.
35. Hausen B., Boeke K., Berry G.J., Segarra I.T., Christians U., Morris R.E. Suppression of acute rejection in allogeneic rat lung transplantation A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine . J Heart Lung Transplant. 18:1999;150-159.